LATS2 and familial pancreatic carcinoma: In pancreatic cancer, miR-181-c is significantly upregulated, correlates with a worse prognosis, and represses the Hippo pathway by directly repressing LATS2, MOB1, MST1, and SAV1, promoting pancreatic cancer cell survival and chemoresistance [53].